Airlines Were on Time in 2020, but Passenger Flights Operated Halved Compared to 2019, Reveals Cirium
4.1.2021 20:15:00 EET | Business Wire | Press release
Over 180 of the major global airlines were on time in 2020, according to a new report by Cirium, the global aviation data company. The Cirium Airline Insights Review 2020 reveals that only 30 major airlines achieved this standard pre-pandemic. But over 60%—or 180 of 300 airlines globally—achieved a 90% or higher on-time arrival percentage since February 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210104005632/en/
Cirium’s new report The Cirium Airline Insights Review 2020 reveals the world’s top 10 busiest airports of 2020. (Graphic: Business Wire)
On-time performance of the top 300 global airlines significantly improved as COVID-19 reduced the number of flights in the air. In 2020, airlines only flew half of the flights flown the previous year.
“The pandemic caused a significant reduction in flight volume with airlines operating 49% fewer flights in 2020. The factors that normally cause flight delays didn’t exist, such as congestion at the airport. Overall global passenger traffic was down in 2020 by 67% from the previous year,” said Jeremy Bowen, CEO of Cirium.
Cirium’s top 10 league table for flights operated by country shows that the majority of flights were operated in the US, despite a 42% year-over-year drop in the market. China maintained its position, with only 24% of that market’s flights down versus 2019.
Japan overtook India, moving up to 3rd place as India’s flights were down 50% versus 2019. The UK was hit heavily with 67% of flights down compared to last year, moving it to 8th place from 5th. Russia moved from 10th place in 2019 to 5th in 2020 and Indonesia moved into the top 10.
|
Top 10 countries by passenger flights flown 2020 |
||||
|
Rank |
Country |
Total flights flown 2020 |
Rank in 2019 |
% YoY diff |
|
1 |
United States |
5.1M |
#1 |
-42% |
|
2 |
China |
3.4M |
#2 |
-24% |
|
3 |
Japan |
638K |
#4 |
-43% |
|
4 |
India |
592K |
#3 |
-50% |
|
5 |
Russia |
486K |
#10 |
-34% |
|
6 |
Brazil |
382K |
#9 |
-53% |
|
7 |
Spain |
352K |
#7 |
-61% |
|
8 |
United Kingdom |
340K |
#5 |
-67% |
|
9 |
Indonesia |
333K |
#12 |
-53% |
|
10 |
Mexico |
332K |
#15 |
-44% |
|
Source: Cirium Core, flights tracked data (passenger flights - narrowbody, widebody and regional) for Jan 1 to Dec 31, date filed Jan 1, 2021 |
||||
Asia-Pacific carriers recovered much quicker in 2020 than their global peers and rose in the rankings in flights operated. Out of the top 10 global airlines, China Southern Airlines’ passenger flights only dropped 28% versus 2019. United Airlines was the most impacted of the top 10, with a 54% drop in flights flown versus 2019.
No European carriers feature in the 2020 list. Ryanair moved to 13th place (from 6th) as the airline’s flights flown were down 72% versus the year before. Lufthansa was 11th in 2019 but missed out on the 2020 top 10, finishing at 29th place as flights flown dropped by 69% in 2020.
|
Top 10 airlines by passenger flights flown 2020 |
|||||
|
Rank |
Airline code |
Airline |
Total flights flown 2020 |
Rank in 2019 |
% YoY diff |
|
1 |
WN |
Southwest Airlines |
896K |
#1 |
-34% |
|
2 |
AA |
American Airlines |
622K |
#3 |
-44% |
|
3 |
DL |
Delta Air Lines |
619K |
#2 |
-46% |
|
4 |
OO |
SkyWest Airlines |
597K |
#4 |
-30% |
|
5 |
CZ |
China Southern Airlines |
521K |
#7 |
-28% |
|
6 |
UA |
United Airlines |
372K |
#5 |
-54% |
|
7 |
MU |
China Eastern Airlines |
321K |
#9 |
-33% |
|
8 |
CA |
Air China |
312K |
#10 |
-30% |
|
9 |
6E |
IndiGo |
281K |
#8 |
-45% |
|
10 |
YX |
Republic Airways |
217K |
#15 |
-37% |
|
Source: Cirium Core, flights tracked data (passenger flights - narrowbody, widebody and regional) for Jan 1 to Dec 31, date filed Jan 1, 2021 |
|||||
“Domestic travel has recovered faster and airlines with a dominant domestic market come back quicker,” Bowen said. “That is especially the case in Asia-Pacific where recovery is more positive. The US and Europe have experienced setbacks with government-enforced restrictions and additional waves of COVID-19 affecting travel.”
Travel restrictions and the shift to more leisure travel versus business travel changed the top 10 league table for flights flown by airport extensively.
Chicago O’Hare is usually the busiest airport globally for passenger flights, however the pandemic caused a 46% reduction in flights for the airport in 2020. Three Chinese airports—Guangzhou Baiyun, Chengdu Shuangliu, and Shenzhen Bao’an—moved into the global top 10 busiest airports by arriving passenger flights.
|
Top 10 airports by passenger flights flown 2020 |
|||||
|
Rank |
Airport code |
Airport |
Total flights flown 2020 |
Rank in 2019 |
% YoY diff |
|
1 |
ATL |
Atlanta US |
260K |
#2 |
-40% |
|
2 |
DFW |
Dallas US |
235K |
#3 |
-30% |
|
3 |
ORD |
Chicago US |
234K |
#1 |
-46% |
|
4 |
DEN |
Denver US |
202K |
#5 |
-32% |
|
5 |
CLT |
Charlotte US |
182K |
#7 |
-32% |
|
6 |
CAN |
Guangzhou CN |
165K |
#13 |
-28% |
|
7 |
LAX |
Los Angeles US |
156K |
#4 |
-50% |
|
8 |
CTU |
Chengdu CN |
148K |
#37 |
-16% |
|
9 |
SZX |
Shenzhen CN |
139K |
#42 |
-16% |
|
10 |
SEA |
Seattle US |
137K |
#18 |
-36% |
|
Source: Cirium Core, flights tracked data (passenger flights - narrowbody, widebody and regional) for Jan 1 to Dec 31, date filed Jan 1, 2021 |
|||||
In 2019, London Heathrow was the 9th busiest airport for flights flown. In 2020, it ranked 31st and flights operating there were down 61% versus 2019. Amsterdam Airport Schiphol was the busiest airport in Europe. Flight operations there dropped 57% in 2020 and as a result the airport sits at 27th globally.
The Cirium Airline Insights Review 2020 provides additional insights on 2020 air travel industry and includes The On-Time Performance Review 2020 by Cirium.
To read the full Cirium Airline Insights Review 2020 – click here.
Ends
Note to editors:
Data for the passenger flights flown is based on set criteria, which includes passenger flights only (including combination flights – passenger and cargo) that are scheduled and aircraft market classes of narrowbody, widebody, and regional jets. It excludes other types, such as cargo and business jet flights, as well as unscheduled flights.
For further information please visit www.cirium.com and follow Cirium updates via LinkedIn and Twitter.
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005632/en/
Contact information
For media enquiries, please contact,
In the UK: Paul Charles / Michael Johnson / Balint Brunner at The PC Agency via cirium@pc.agency or +44 207 768 0001
In the Americas: Mike Arnot, at Juliett Alpha via cirium@juliettalpha.com
In Asia-Pacific: Tracy Cheung, at Cirium via tracy.cheung@cirium.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
